{"recordsFiltered":48602,"recordsTotal":48602,"next":"http://staging-fdaaa.ebmdatalab.net/api/trials/?format=json&length=300&ordering=status&start=44700","previous":"http://staging-fdaaa.ebmdatalab.net/api/trials/?format=json&length=300&ordering=status&start=44100","results":[{"registry_id":"NCT07237737","publication_url":"https://clinicaltrials.gov/study/NCT07237737","title":"Wound Healing Outcomes With and Without the Alexis Wound Retractor in Direct Anterior Approach Total Hip Arthroplasty","has_exemption":false,"start_date":"2026-12-31","completion_date":"2028-01-31","has_results":false,"results_due":false,"sponsor_name":"University of Miami","sponsor_slug":"university-of-miami","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05179577","publication_url":"https://clinicaltrials.gov/study/NCT05179577","title":"A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis (Study OS440-3006)","has_exemption":false,"start_date":"2027-01-31","completion_date":"2028-01-31","has_results":false,"results_due":false,"sponsor_name":"RVL Pharmaceuticals, Inc.","sponsor_slug":"rvl-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT01515527","publication_url":"https://clinicaltrials.gov/study/NCT01515527","title":"Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","has_exemption":false,"start_date":"2012-02-07","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT04107181","publication_url":"https://clinicaltrials.gov/study/NCT04107181","title":"A Pilot Study Continuation to Assess the Use of an Introducer \"Calla\" During Cervical Cancer Screening","has_exemption":false,"start_date":"2016-04-14","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Duke University","sponsor_slug":"duke-university","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02977780","publication_url":"https://clinicaltrials.gov/study/NCT02977780","title":"INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)","has_exemption":false,"start_date":"2017-02-09","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Patrick Wen, MD","sponsor_slug":"patrick-wen-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03934372","publication_url":"https://clinicaltrials.gov/study/NCT03934372","title":"An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants","has_exemption":false,"start_date":"2020-01-29","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Incyte Biosciences International Sàrl","sponsor_slug":"incyte-biosciences-international-sarl","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04620187","publication_url":"https://clinicaltrials.gov/study/NCT04620187","title":"A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas","has_exemption":false,"start_date":"2020-12-24","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Dana-Farber Cancer Institute","sponsor_slug":"dana-farber-cancer-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05039632","publication_url":"https://clinicaltrials.gov/study/NCT05039632","title":"Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies","has_exemption":false,"start_date":"2023-05-08","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05949099","publication_url":"https://clinicaltrials.gov/study/NCT05949099","title":"Phase II Study of Cryoablation and Nirogacestat for Desmoid Tumor","has_exemption":false,"start_date":"2023-08-15","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Nam Bui","sponsor_slug":"nam-bui","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05819853","publication_url":"https://clinicaltrials.gov/study/NCT05819853","title":"Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome","has_exemption":false,"start_date":"2023-11-03","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"University of Colorado, Denver","sponsor_slug":"university-of-colorado-denver","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05386394","publication_url":"https://clinicaltrials.gov/study/NCT05386394","title":"Phase II Clinical Trial of Transcranial Direct Current Stimulation in the Treatment of Primary Progressive Aphasia","has_exemption":false,"start_date":"2024-02-13","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Johns Hopkins University","sponsor_slug":"johns-hopkins-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06127407","publication_url":"https://clinicaltrials.gov/study/NCT06127407","title":"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled Study of Ivosidenib in Participants ≥18 Years of Age With Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen","has_exemption":false,"start_date":"2024-07-09","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Servier Bio-Innovation LLC","sponsor_slug":"servier-bio-innovation-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06336655","publication_url":"https://clinicaltrials.gov/study/NCT06336655","title":"Physiology of Unloading VA ECMO Trial","has_exemption":false,"start_date":"2024-10-02","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"University of Utah","sponsor_slug":"university-of-utah","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06617858","publication_url":"https://clinicaltrials.gov/study/NCT06617858","title":"Open-label Phase 2 Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment","has_exemption":false,"start_date":"2024-12-04","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06867549","publication_url":"https://clinicaltrials.gov/study/NCT06867549","title":"Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) Stage II","has_exemption":false,"start_date":"2025-03-04","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06940180","publication_url":"https://clinicaltrials.gov/study/NCT06940180","title":"Perioperative Chemoimmunotherapy With Toripalimab for Sinonasal Cancer","has_exemption":false,"start_date":"2025-06-17","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Glenn J. Hanna","sponsor_slug":"glenn-j-hanna","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05999383","publication_url":"https://clinicaltrials.gov/study/NCT05999383","title":"Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration","has_exemption":false,"start_date":"2025-07-01","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04433572","publication_url":"https://clinicaltrials.gov/study/NCT04433572","title":"Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Temsirolimus Perivascular Injection 0.1 mg/mL on the Incidence of Ischemia-Driven Major Amputation, Clinically Driven Target Lesion Revascularization, and Clinically Relevant Target Lesion Occlusion After Revascularization of Lesions Below the Knee in Patients With Symptomatic Rutherford 3-5 Peripheral Artery Disease","has_exemption":false,"start_date":"2025-07-30","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Mercator MedSystems, Inc.","sponsor_slug":"mercator-medsystems-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06445166","publication_url":"https://clinicaltrials.gov/study/NCT06445166","title":"A Multicenter Phase II Study of Propranolol for the Treatment of Kaposi Sarcoma in Adults","has_exemption":false,"start_date":"2025-08-20","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07133425","publication_url":"https://clinicaltrials.gov/study/NCT07133425","title":"A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer","has_exemption":false,"start_date":"2025-11-06","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07085338","publication_url":"https://clinicaltrials.gov/study/NCT07085338","title":"A Phase II Study With a Safety Run-In of the Addition of N-803, a Novel IL-15 Super-Agonist, to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma","has_exemption":false,"start_date":"2025-11-10","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"St. Jude Children's Research Hospital","sponsor_slug":"st-jude-childrens-research-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07213466","publication_url":"https://clinicaltrials.gov/study/NCT07213466","title":"Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder - OBOE-Mayo","has_exemption":false,"start_date":"2026-01-19","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07009899","publication_url":"https://clinicaltrials.gov/study/NCT07009899","title":"BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Medical College of Wisconsin","sponsor_slug":"medical-college-of-wisconsin","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07441122","publication_url":"https://clinicaltrials.gov/study/NCT07441122","title":"Building Cognitive Reserve Through Brain-Computer-Interfaces","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"University of Texas at Austin","sponsor_slug":"university-of-texas-at-austin","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07461961","publication_url":"https://clinicaltrials.gov/study/NCT07461961","title":"CORTISHOCK-P: A Randomized Pilot Trial of Corticosteroids as a Pharmacologic Adjunct to Temporary Mechanical Circulatory Support in Inflammation-Enriched Heart Failure Cardiogenic Shock","has_exemption":false,"start_date":"2026-07-01","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Brigham and Women's Hospital","sponsor_slug":"brigham-and-womens-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07477054","publication_url":"https://clinicaltrials.gov/study/NCT07477054","title":"A Post-Approval Multicenter Study to Assess the Continued Safety and Effectiveness of the AeroPace® System - The AERO-PAS Study","has_exemption":false,"start_date":"2026-07-01","completion_date":"2028-02-01","has_results":false,"results_due":false,"sponsor_name":"Lungpacer Medical Inc.","sponsor_slug":"lungpacer-medical-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07205822","publication_url":"https://clinicaltrials.gov/study/NCT07205822","title":"A Phase IIIb, Open-label, Multinational Study Assessing the Efficacy and Safety of Dato-DXd Treatment in Patients With HRpositive, HER2 IHC 0, Locally Advanced Inoperable or Metastatic Breast Cancer Refractory to Endocrine Therapy (TROPION-Breast06)","has_exemption":false,"start_date":"2025-10-30","completion_date":"2028-02-02","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06813911","publication_url":"https://clinicaltrials.gov/study/NCT06813911","title":"A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C and Lp(a)","has_exemption":false,"start_date":"2025-04-30","completion_date":"2028-02-03","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07219407","publication_url":"https://clinicaltrials.gov/study/NCT07219407","title":"An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures","has_exemption":false,"start_date":"2025-12-15","completion_date":"2028-02-03","has_results":false,"results_due":false,"sponsor_name":"Rapport Therapeutics Inc.","sponsor_slug":"rapport-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06830798","publication_url":"https://clinicaltrials.gov/study/NCT06830798","title":"A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation","has_exemption":false,"start_date":"2025-05-19","completion_date":"2028-02-04","has_results":false,"results_due":false,"sponsor_name":"Alexion Pharmaceuticals, Inc.","sponsor_slug":"alexion-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07223138","publication_url":"https://clinicaltrials.gov/study/NCT07223138","title":"A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis","has_exemption":false,"start_date":"2025-11-13","completion_date":"2028-02-04","has_results":false,"results_due":false,"sponsor_name":"MoonLake Immunotherapeutics AG","sponsor_slug":"moonlake-immunotherapeutics-ag","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03173924","publication_url":"https://clinicaltrials.gov/study/NCT03173924","title":"Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer","has_exemption":false,"start_date":"2017-06-06","completion_date":"2028-02-06","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06091254","publication_url":"https://clinicaltrials.gov/study/NCT06091254","title":"A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)","has_exemption":false,"start_date":"2023-12-12","completion_date":"2028-02-07","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03946878","publication_url":"https://clinicaltrials.gov/study/NCT03946878","title":"An Open Label, Phase II Investigator Initiated Study of Venetoclax and Acalabrutinib in Previously Treated Relapsed/Refractory Patients With Mantle Cell Lymphoma (MCL)","has_exemption":false,"start_date":"2019-08-13","completion_date":"2028-02-08","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04771130","publication_url":"https://clinicaltrials.gov/study/NCT04771130","title":"A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies","has_exemption":false,"start_date":"2021-05-24","completion_date":"2028-02-08","has_results":false,"results_due":false,"sponsor_name":"BeiGene","sponsor_slug":"beigene","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06456463","publication_url":"https://clinicaltrials.gov/study/NCT06456463","title":"A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy","has_exemption":false,"start_date":"2025-01-14","completion_date":"2028-02-09","has_results":false,"results_due":false,"sponsor_name":"Stemline Therapeutics, Inc.","sponsor_slug":"stemline-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07219043","publication_url":"https://clinicaltrials.gov/study/NCT07219043","title":"A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants With Late Isolated Microvascular Inflammation (MVI)","has_exemption":false,"start_date":"2026-01-05","completion_date":"2028-02-10","has_results":false,"results_due":false,"sponsor_name":"Biogen","sponsor_slug":"biogen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06525636","publication_url":"https://clinicaltrials.gov/study/NCT06525636","title":"A Multicenter, Open-label, Phase 1/2, Dose-escalation and Subsequent Safety Extension Study of Subcutaneous KK8123 in Adult Patients With X-linked Hypophosphatemia","has_exemption":false,"start_date":"2024-10-09","completion_date":"2028-02-11","has_results":false,"results_due":false,"sponsor_name":"Kyowa Kirin Co., Ltd.","sponsor_slug":"kyowa-kirin-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07516951","publication_url":"https://clinicaltrials.gov/study/NCT07516951","title":"A Phase IIb, Multicentre, Randomised, Double Blind, Placebo Controlled, Three-arm Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability at Week 24 of 2 Doses of CHF10067 (Zampilimab), With an Optional 24-week Double Blind, Placebo Controlled Extension Phase in Participants With Idiopathic Pulmonary Fibrosis","has_exemption":false,"start_date":"2026-06-01","completion_date":"2028-02-12","has_results":false,"results_due":false,"sponsor_name":"Chiesi Farmaceutici S.p.A.","sponsor_slug":"chiesi-farmaceutici-spa","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06708754","publication_url":"https://clinicaltrials.gov/study/NCT06708754","title":"PBM-LEF Study: The Impact of PBM on Biomarkers of Radiation Lymphedema and Fibrosis in Head and Neck Cancer Patients: A Feasibility Study","has_exemption":false,"start_date":"2025-02-13","completion_date":"2028-02-13","has_results":false,"results_due":false,"sponsor_name":"NYU Langone Health","sponsor_slug":"nyu-langone-health","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05201066","publication_url":"https://clinicaltrials.gov/study/NCT05201066","title":"An Open-label, Multicenter, Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.","has_exemption":false,"start_date":"2023-02-13","completion_date":"2028-02-14","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06581198","publication_url":"https://clinicaltrials.gov/study/NCT06581198","title":"A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients With Active, Refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN).","has_exemption":false,"start_date":"2024-09-04","completion_date":"2028-02-14","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06311721","publication_url":"https://clinicaltrials.gov/study/NCT06311721","title":"A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2024-09-09","completion_date":"2028-02-14","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06542250","publication_url":"https://clinicaltrials.gov/study/NCT06542250","title":"A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)","has_exemption":false,"start_date":"2024-09-18","completion_date":"2028-02-14","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05363709","publication_url":"https://clinicaltrials.gov/study/NCT05363709","title":"A Phase 2 Study to Assess the Effect of BALSTILIMAB (AGEN2034) on Viral Clearance in HPV-positive Oropharyngeal Cancer Patients With Persistent HPV Detection in Plasma cfDNA After Definitive Therapy","has_exemption":false,"start_date":"2023-10-18","completion_date":"2028-02-15","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06747585","publication_url":"https://clinicaltrials.gov/study/NCT06747585","title":"A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+Squamous Solid Tumors","has_exemption":false,"start_date":"2024-12-16","completion_date":"2028-02-15","has_results":false,"results_due":false,"sponsor_name":"Alentis Therapeutics AG","sponsor_slug":"alentis-therapeutics-ag","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06948448","publication_url":"https://clinicaltrials.gov/study/NCT06948448","title":"A Randomized, Open Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo® in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care for First-line Treatment of Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer","has_exemption":false,"start_date":"2025-11-18","completion_date":"2028-02-15","has_results":false,"results_due":false,"sponsor_name":"Ono Pharmaceutical Co. Ltd","sponsor_slug":"ono-pharmaceutical-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07415031","publication_url":"https://clinicaltrials.gov/study/NCT07415031","title":"Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)","has_exemption":false,"start_date":"2026-05-16","completion_date":"2028-02-16","has_results":false,"results_due":false,"sponsor_name":"Mirati Therapeutics Inc.","sponsor_slug":"mirati-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05677971","publication_url":"https://clinicaltrials.gov/study/NCT05677971","title":"A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis","has_exemption":false,"start_date":"2023-03-06","completion_date":"2028-02-17","has_results":false,"results_due":false,"sponsor_name":"Takeda","sponsor_slug":"takeda","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06706622","publication_url":"https://clinicaltrials.gov/study/NCT06706622","title":"Interventional, Randomized, Double-blind, Placebo-controlled, Optional Open-label Extension Trial of Lu AF82422 in Participants With Multiple System Atrophy","has_exemption":false,"start_date":"2024-12-03","completion_date":"2028-02-17","has_results":false,"results_due":false,"sponsor_name":"H. Lundbeck A/S","sponsor_slug":"h-lundbeck-as","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06627244","publication_url":"https://clinicaltrials.gov/study/NCT06627244","title":"Phase 2, Single Arm Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma","has_exemption":false,"start_date":"2025-02-14","completion_date":"2028-02-17","has_results":false,"results_due":false,"sponsor_name":"University of Miami","sponsor_slug":"university-of-miami","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07007793","publication_url":"https://clinicaltrials.gov/study/NCT07007793","title":"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism","has_exemption":false,"start_date":"2025-08-07","completion_date":"2028-02-18","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03850418","publication_url":"https://clinicaltrials.gov/study/NCT03850418","title":"Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant","has_exemption":false,"start_date":"2019-07-01","completion_date":"2028-02-20","has_results":false,"results_due":false,"sponsor_name":"Henry Ford Health System","sponsor_slug":"henry-ford-health-system","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06843434","publication_url":"https://clinicaltrials.gov/study/NCT06843434","title":"A Phase II Study of Neoadjuvant Botensilimab and Balstilimab Immunotherapy for Mismatch Repair Proficient Rectal Adenocarcinoma","has_exemption":false,"start_date":"2025-02-20","completion_date":"2028-02-20","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06512883","publication_url":"https://clinicaltrials.gov/study/NCT06512883","title":"Phase 3, Open-label Trial to Evaluate Safety, Pharmacokinetics, and Efficacy of Benralizumab in Children With Eosinophilic Diseases (CLIPS)","has_exemption":false,"start_date":"2025-04-17","completion_date":"2028-02-21","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06439485","publication_url":"https://clinicaltrials.gov/study/NCT06439485","title":"Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion","has_exemption":false,"start_date":"2024-11-19","completion_date":"2028-02-22","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07244263","publication_url":"https://clinicaltrials.gov/study/NCT07244263","title":"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa","has_exemption":false,"start_date":"2026-01-26","completion_date":"2028-02-22","has_results":false,"results_due":false,"sponsor_name":"Takeda","sponsor_slug":"takeda","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04083495","publication_url":"https://clinicaltrials.gov/study/NCT04083495","title":"Phase II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Peripheral T Cell Lymphoma","has_exemption":false,"start_date":"2019-09-17","completion_date":"2028-02-23","has_results":false,"results_due":false,"sponsor_name":"UNC Lineberger Comprehensive Cancer Center","sponsor_slug":"unc-lineberger-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06198712","publication_url":"https://clinicaltrials.gov/study/NCT06198712","title":"A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease","has_exemption":false,"start_date":"2023-01-12","completion_date":"2028-02-23","has_results":false,"results_due":false,"sponsor_name":"Forma Therapeutics, Inc.","sponsor_slug":"forma-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06268873","publication_url":"https://clinicaltrials.gov/study/NCT06268873","title":"A Phase III, Randomised, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination With Dapagliflozin Compared With Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participants With CKD and High Blood Pressure","has_exemption":false,"start_date":"2024-03-29","completion_date":"2028-02-24","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06866405","publication_url":"https://clinicaltrials.gov/study/NCT06866405","title":"A Phase 3 Study to Investigate the Safety, Tolerability, and Immunogenicity of Revaccinating Pregnant Participants During Subsequent Pregnancies and Persistence of Immunity of a Single Dose of a Bivalent Respiratory Syncytial Virus (RSV) Vaccine.","has_exemption":false,"start_date":"2025-04-16","completion_date":"2028-02-24","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06744920","publication_url":"https://clinicaltrials.gov/study/NCT06744920","title":"A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase","has_exemption":false,"start_date":"2025-02-07","completion_date":"2028-02-25","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06795022","publication_url":"https://clinicaltrials.gov/study/NCT06795022","title":"A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T Cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants With Advanced or Metastatic Solid Tumours (RHEA-1)","has_exemption":false,"start_date":"2025-03-27","completion_date":"2028-02-25","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07096908","publication_url":"https://clinicaltrials.gov/study/NCT07096908","title":"Treatment With Tirzepatide of the Disease of Obesity in People With Type 1 Diabetes","has_exemption":false,"start_date":"2025-07-31","completion_date":"2028-02-25","has_results":false,"results_due":false,"sponsor_name":"Dasman Diabetes Institute","sponsor_slug":"dasman-diabetes-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02162849","publication_url":"https://clinicaltrials.gov/study/NCT02162849","title":"The Effects of Behavioral Counseling Plus Nicotine Replacement Therapy (NRT) or Varenicline on Smoking Cessation Among Smokers High and Low in Intrinsic Reward Sensitivity","has_exemption":false,"start_date":"2015-12-14","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT03074812","publication_url":"https://clinicaltrials.gov/study/NCT03074812","title":"Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stimulation","has_exemption":false,"start_date":"2016-02-29","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Johns Hopkins University","sponsor_slug":"johns-hopkins-university","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT03438747","publication_url":"https://clinicaltrials.gov/study/NCT03438747","title":"An Assessment of P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion With Instrumentation","has_exemption":false,"start_date":"2018-04-24","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"CeraPedics, Inc","sponsor_slug":"cerapedics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03586453","publication_url":"https://clinicaltrials.gov/study/NCT03586453","title":"A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer","has_exemption":false,"start_date":"2018-08-13","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Dana-Farber Cancer Institute","sponsor_slug":"dana-farber-cancer-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03887715","publication_url":"https://clinicaltrials.gov/study/NCT03887715","title":"A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression","has_exemption":false,"start_date":"2019-09-26","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"LivaNova","sponsor_slug":"livanova","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03282396","publication_url":"https://clinicaltrials.gov/study/NCT03282396","title":"Phase II Trial of Ibrutinib in Perviously Untreated High Risk Smoldering Mantle Cell Lymphoma (MCL)","has_exemption":false,"start_date":"2020-06-08","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04610866","publication_url":"https://clinicaltrials.gov/study/NCT04610866","title":"Evaluation of the Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat","has_exemption":false,"start_date":"2020-12-09","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","sponsor_slug":"national-heart-lung-and-blood-institute-nhlbi","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04380545","publication_url":"https://clinicaltrials.gov/study/NCT04380545","title":"A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma","has_exemption":false,"start_date":"2021-01-13","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04931342","publication_url":"https://clinicaltrials.gov/study/NCT04931342","title":"A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","has_exemption":false,"start_date":"2021-10-07","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04712539","publication_url":"https://clinicaltrials.gov/study/NCT04712539","title":"Efficacy of Combination Baloxovir and Oseltamivir Therapy in Influenza Infected Immunocompromised Hosts","has_exemption":false,"start_date":"2021-10-11","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05037760","publication_url":"https://clinicaltrials.gov/study/NCT05037760","title":"A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination With Ruxolitinib in Participants With Myelofibrosis","has_exemption":false,"start_date":"2021-12-16","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Takeda","sponsor_slug":"takeda","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05064280","publication_url":"https://clinicaltrials.gov/study/NCT05064280","title":"Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases","has_exemption":false,"start_date":"2022-01-20","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04966481","publication_url":"https://clinicaltrials.gov/study/NCT04966481","title":"Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial","has_exemption":false,"start_date":"2022-04-06","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Washington University School of Medicine","sponsor_slug":"washington-university-school-of-medicine","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05594992","publication_url":"https://clinicaltrials.gov/study/NCT05594992","title":"An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects","has_exemption":false,"start_date":"2023-02-22","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"JCR Pharmaceuticals Co., Ltd.","sponsor_slug":"jcr-pharmaceuticals-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05816382","publication_url":"https://clinicaltrials.gov/study/NCT05816382","title":"A Long-term Extension Study to Evaluate the Safety and Tolerability of TAK-861 in Participants With Selected Central Hypersomnia Conditions","has_exemption":false,"start_date":"2023-04-05","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Takeda","sponsor_slug":"takeda","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05546554","publication_url":"https://clinicaltrials.gov/study/NCT05546554","title":"Randomized Placebo-Controlled Crossover Trial of Suvorexant for Sleep in Children With Autism","has_exemption":false,"start_date":"2023-08-09","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Stanford University","sponsor_slug":"stanford-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06331052","publication_url":"https://clinicaltrials.gov/study/NCT06331052","title":"3-D Tractography Focused Ultrasound Ablation for Essential Tremor","has_exemption":false,"start_date":"2024-02-28","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"University of North Carolina, Chapel Hill","sponsor_slug":"university-of-north-carolina-chapel-hill","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05987644","publication_url":"https://clinicaltrials.gov/study/NCT05987644","title":"DURABLE: Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and rEarrangements","has_exemption":false,"start_date":"2024-03-07","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Joshua Palmer","sponsor_slug":"joshua-palmer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06564038","publication_url":"https://clinicaltrials.gov/study/NCT06564038","title":"A Phase I/II Open-Label Multi-Centre Master Protocol to Evaluate the Safety and Efficacy of AZD0486 Monotherapy or in Combination With Other Anticancer Agents in Participants With Mature B-Cell Malignancies","has_exemption":false,"start_date":"2025-01-30","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06964269","publication_url":"https://clinicaltrials.gov/study/NCT06964269","title":"A Phase 4 Pilot Study With Extension to Assess the Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease and the Effect on Corneal Nerves and Neuropathic Corneal Pain","has_exemption":false,"start_date":"2025-02-11","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Toyos Clinic","sponsor_slug":"toyos-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06831149","publication_url":"https://clinicaltrials.gov/study/NCT06831149","title":"A Phase 2 Trial of Intraoperative Fluorescent Angiography to Decrease Pharyngocutaneous Fistula Rates in Patients Undergoing Hypopharyngeal Reconstruction","has_exemption":false,"start_date":"2025-02-28","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Matthew Spector","sponsor_slug":"matthew-spector","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06855498","publication_url":"https://clinicaltrials.gov/study/NCT06855498","title":"A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib","has_exemption":false,"start_date":"2025-02-28","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Incyte Corporation","sponsor_slug":"incyte-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06810375","publication_url":"https://clinicaltrials.gov/study/NCT06810375","title":"Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery","has_exemption":false,"start_date":"2025-03-01","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"George Washington University","sponsor_slug":"george-washington-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06819670","publication_url":"https://clinicaltrials.gov/study/NCT06819670","title":"A Multicenter Pilot Clinical Trial to Prevent Infantile Spasms Relapse","has_exemption":false,"start_date":"2025-05-05","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"University of California, Los Angeles","sponsor_slug":"university-of-california-los-angeles","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07218679","publication_url":"https://clinicaltrials.gov/study/NCT07218679","title":"Clinical Trial on the Use of Stratafix Symmetric vs. Resorbable Monofilament for Closure of Large Median Laparotomy in Oncological Patients","has_exemption":false,"start_date":"2025-05-21","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","sponsor_slug":"fundacion-publica-andaluza-para-la-gestion-de-la-investigacion-en-sevilla","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06817018","publication_url":"https://clinicaltrials.gov/study/NCT06817018","title":"Ginger and the Microbiota-gut-brain Connection in Sciatic Pain Individuals","has_exemption":false,"start_date":"2025-07-01","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Leslie Shen","sponsor_slug":"leslie-shen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07048262","publication_url":"https://clinicaltrials.gov/study/NCT07048262","title":"A Phase 2b, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 Years) With Non-cystic Fibrosis Bronchiectasis","has_exemption":false,"start_date":"2025-09-03","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"CSL Behring","sponsor_slug":"csl-behring","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07284875","publication_url":"https://clinicaltrials.gov/study/NCT07284875","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes","has_exemption":false,"start_date":"2025-12-18","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Kailera","sponsor_slug":"kailera","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07287917","publication_url":"https://clinicaltrials.gov/study/NCT07287917","title":"A Phase 1b/2 Trial Investigating the Safety and Efficacy of Oral AMXT 1501 and Oral DFMO in Combination With Standard of Care in Patients With Advanced Solid Tumors Who Progressed After Prior Therapies","has_exemption":false,"start_date":"2026-01-26","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Aminex Therapeutics, Inc.","sponsor_slug":"aminex-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06704100","publication_url":"https://clinicaltrials.gov/study/NCT06704100","title":"A Phase 2, Randomized, Double-blind, Placebo-controlled Trial of Fosamprenavir-Sodium Alginate Administered Orally for 8 Weeks to Patients With Proton Pump Inhibitor Refractory Gastroesophageal Reflux Disease","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Medical College of Wisconsin","sponsor_slug":"medical-college-of-wisconsin","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06948084","publication_url":"https://clinicaltrials.gov/study/NCT06948084","title":"A Randomized Phase II Trial for High-Risk Multiple Myeloma That is Refractory or in First Relapse With Daratumumab, Teclistamab (DT) Versus Daratumumab, Pomalidomide, Dexamethasone (DPd) or Daratumumab, Carfilzomib, Dexamethasone (DKd)","has_exemption":false,"start_date":"2026-04-29","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06674109","publication_url":"https://clinicaltrials.gov/study/NCT06674109","title":"SAVE-Care (SGLT2i As Novel Gout Care) Trial","has_exemption":false,"start_date":"2026-04-30","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03833206","publication_url":"https://clinicaltrials.gov/study/NCT03833206","title":"A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients: Part I Dose Escalation","has_exemption":false,"start_date":"2027-01-15","completion_date":"2028-02-28","has_results":false,"results_due":false,"sponsor_name":"BioLite, Inc.","sponsor_slug":"biolite-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT02679144","publication_url":"https://clinicaltrials.gov/study/NCT02679144","title":"NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)","has_exemption":false,"start_date":"2016-02-29","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Giselle Sholler","sponsor_slug":"giselle-sholler","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT03093116","publication_url":"https://clinicaltrials.gov/study/NCT03093116","title":"A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)","has_exemption":false,"start_date":"2017-03-07","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Turning Point Therapeutics, Inc.","sponsor_slug":"turning-point-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04524611","publication_url":"https://clinicaltrials.gov/study/NCT04524611","title":"A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF Therapy","has_exemption":false,"start_date":"2020-09-30","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04337580","publication_url":"https://clinicaltrials.gov/study/NCT04337580","title":"A Phase II Trial of FASN Inhibition by Omeprazole in Combination With Cabazitaxel in Patients With Docetaxel- and Castration-Resistant Prostate Cancer","has_exemption":false,"start_date":"2021-03-05","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Wake Forest University Health Sciences","sponsor_slug":"wake-forest-university-health-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04779554","publication_url":"https://clinicaltrials.gov/study/NCT04779554","title":"A Randomized Phase 2 Trial of Flat Dose vs. Weight-based Dose of Intra-peritoneal (IP) Chemotherapy for Patients Undergoing Cytoreductive Surgery and Heated Intra-peritoneal Chemotherapy (CRS/HIPEC) for Advanced Gastrointestinal Malignancy","has_exemption":false,"start_date":"2021-06-04","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Prakash Pandalai","sponsor_slug":"prakash-pandalai","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05130450","publication_url":"https://clinicaltrials.gov/study/NCT05130450","title":"An Open-Label Extension Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)","has_exemption":false,"start_date":"2021-11-18","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Ionis Pharmaceuticals, Inc.","sponsor_slug":"ionis-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05215340","publication_url":"https://clinicaltrials.gov/study/NCT05215340","title":"A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)","has_exemption":false,"start_date":"2022-03-04","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Daiichi Sankyo","sponsor_slug":"daiichi-sankyo","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04704505","publication_url":"https://clinicaltrials.gov/study/NCT04704505","title":"Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) (BAT-RAD Study)","has_exemption":false,"start_date":"2022-04-28","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","sponsor_slug":"sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05456880","publication_url":"https://clinicaltrials.gov/study/NCT05456880","title":"A Phase 1/2 Study Evaluating the Safety and Efficacy of a Single Dose of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) in Patients With Sickle Cell Disease and Severe Vaso-Occlusive Crises (Beacon Trial)","has_exemption":false,"start_date":"2022-08-30","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Beam Therapeutics Inc.","sponsor_slug":"beam-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05529316","publication_url":"https://clinicaltrials.gov/study/NCT05529316","title":"A Multicohort, Open Label, Phase 2 Study of Botensilimab (AGEN1181) for Treatment of Advanced Melanoma Refractory to Prior Checkpoint Inhibitor Therapy","has_exemption":false,"start_date":"2022-12-12","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Agenus Inc.","sponsor_slug":"agenus-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04905914","publication_url":"https://clinicaltrials.gov/study/NCT04905914","title":"A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, And Preliminary Efficacy Study Of Oral ATRN-119 In Patients With Advanced Solid Tumors","has_exemption":false,"start_date":"2023-01-09","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Aprea Therapeutics","sponsor_slug":"aprea-therapeutics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05573126","publication_url":"https://clinicaltrials.gov/study/NCT05573126","title":"A Modular, Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 as Monotherapy and in Combination in Patients With Relapsed Locally Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer","has_exemption":false,"start_date":"2023-01-11","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Ellipses Pharma","sponsor_slug":"ellipses-pharma","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05783609","publication_url":"https://clinicaltrials.gov/study/NCT05783609","title":"A Phase 2 Study of Epcoritamab and Rituximab for First-line Treatment of Follicular Lymphoma","has_exemption":false,"start_date":"2023-06-21","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Reid Merryman, MD","sponsor_slug":"reid-merryman-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05537896","publication_url":"https://clinicaltrials.gov/study/NCT05537896","title":"Prospective Evaluation of Xerava™ (Eravacycline) Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia","has_exemption":false,"start_date":"2024-02-19","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"West Virginia University","sponsor_slug":"west-virginia-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06260709","publication_url":"https://clinicaltrials.gov/study/NCT06260709","title":"Open-label Extension Study of Long-term Safety and Efficacy of NNC6019-0001 in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)","has_exemption":false,"start_date":"2024-02-20","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Novo Nordisk A/S","sponsor_slug":"novo-nordisk-as","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06161025","publication_url":"https://clinicaltrials.gov/study/NCT06161025","title":"A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","has_exemption":false,"start_date":"2024-02-27","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Daiichi Sankyo","sponsor_slug":"daiichi-sankyo","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05913388","publication_url":"https://clinicaltrials.gov/study/NCT05913388","title":"Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin-3 Inhibitor (GB1211) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma","has_exemption":false,"start_date":"2024-02-29","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Providence Health & Services","sponsor_slug":"providence-health-services","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06191562","publication_url":"https://clinicaltrials.gov/study/NCT06191562","title":"Randomized Clinical Trial of Post-operative Outcomes Following Posterior Versus Anterior Tympanostomy Tube Placement","has_exemption":false,"start_date":"2024-02-29","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"David Chi, MD","sponsor_slug":"david-chi-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06111781","publication_url":"https://clinicaltrials.gov/study/NCT06111781","title":"The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer","has_exemption":false,"start_date":"2024-04-15","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Yale University","sponsor_slug":"yale-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06384807","publication_url":"https://clinicaltrials.gov/study/NCT06384807","title":"A Phase 1/2, First in Human, Dose Escalation and Dose Expansion Study of BHV-1510 (Previously PBI-410) as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors","has_exemption":false,"start_date":"2024-04-22","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Biohaven Therapeutics Ltd.","sponsor_slug":"biohaven-therapeutics-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05681195","publication_url":"https://clinicaltrials.gov/study/NCT05681195","title":"Zanubrutinib With Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial With a Safety Lead-In","has_exemption":false,"start_date":"2024-04-25","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Baptist Health South Florida","sponsor_slug":"baptist-health-south-florida","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06504147","publication_url":"https://clinicaltrials.gov/study/NCT06504147","title":"A Phase 2, Randomised, Open Label, Multicentre Study of an Intraperitoneal α-emitting Radionuclide Therapy (Radspherin®) in Patients With Primary Advanced High-grade Serous or High-grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient and Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","has_exemption":false,"start_date":"2024-06-15","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Oncoinvent Solutions AS","sponsor_slug":"oncoinvent-solutions-as","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06496178","publication_url":"https://clinicaltrials.gov/study/NCT06496178","title":"A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma","has_exemption":false,"start_date":"2024-06-25","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Merus B.V.","sponsor_slug":"merus-bv","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06437574","publication_url":"https://clinicaltrials.gov/study/NCT06437574","title":"Lowering Cholesterol in Prostate Cancer to Target Rapamycin-Insensitive Companion Of MTOR (TORC2) in T-Cell Surface Glycoprotein CD8 Alpha Chain (CD8+) Lymphocytes","has_exemption":false,"start_date":"2024-07-16","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Cedars-Sinai Medical Center","sponsor_slug":"cedars-sinai-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06388083","publication_url":"https://clinicaltrials.gov/study/NCT06388083","title":"A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease","has_exemption":false,"start_date":"2024-07-31","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Belite Bio, Inc","sponsor_slug":"belite-bio-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06455787","publication_url":"https://clinicaltrials.gov/study/NCT06455787","title":"J-Valve to Treat Aortic Regurgitation Via Transcatheter Therapy","has_exemption":false,"start_date":"2024-10-17","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"JC Medical, Inc., an affiliate of Edwards Lifesciences LLC","sponsor_slug":"jc-medical-inc-an-affiliate-of-edwards-lifesciences-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06310031","publication_url":"https://clinicaltrials.gov/study/NCT06310031","title":"Investigation of a Novel, magNetically Levitated VAD for the Treatment of refractOry Left Ventricular heArT failurE","has_exemption":false,"start_date":"2024-10-28","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"BrioHealth Solutions, Inc.","sponsor_slug":"briohealth-solutions-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06532656","publication_url":"https://clinicaltrials.gov/study/NCT06532656","title":"A Phase 2/3, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1","has_exemption":false,"start_date":"2024-11-20","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Gilead Sciences","sponsor_slug":"gilead-sciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06336798","publication_url":"https://clinicaltrials.gov/study/NCT06336798","title":"Effect of Pioglitazone on Mitochondrial Metabolism in Pulmonary Hypertension Due to Chronic Lung Disease","has_exemption":false,"start_date":"2024-12-17","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Emory University","sponsor_slug":"emory-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06568939","publication_url":"https://clinicaltrials.gov/study/NCT06568939","title":"A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2025-01-20","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06092333","publication_url":"https://clinicaltrials.gov/study/NCT06092333","title":"A Pilot Study of the Combination of VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B","has_exemption":false,"start_date":"2025-01-31","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","sponsor_slug":"national-institute-of-diabetes-and-digestive-and-kidney-diseases-niddk","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06699602","publication_url":"https://clinicaltrials.gov/study/NCT06699602","title":"A Pilot Phase II Study of Neoadjuvant Cemiplimab + Fianlimab in Patients With Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy","has_exemption":false,"start_date":"2025-02-11","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Memorial Sloan Kettering Cancer Center","sponsor_slug":"memorial-sloan-kettering-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06534060","publication_url":"https://clinicaltrials.gov/study/NCT06534060","title":"A Phase 2, Open-label, Multicenter Study of MB-105 in Patients With CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL).","has_exemption":false,"start_date":"2025-02-15","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"March Biosciences Inc","sponsor_slug":"march-biosciences-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06902311","publication_url":"https://clinicaltrials.gov/study/NCT06902311","title":"Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)","has_exemption":false,"start_date":"2025-02-19","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"UNC Lineberger Comprehensive Cancer Center","sponsor_slug":"unc-lineberger-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06824792","publication_url":"https://clinicaltrials.gov/study/NCT06824792","title":"Real-world Study to Investigate Optimal Standard Treatment Selection for Solid Tumor Patients by Guided by Biologically-informed Multi-agent System","has_exemption":false,"start_date":"2025-03-01","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"NING LI","sponsor_slug":"ning-li","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06522737","publication_url":"https://clinicaltrials.gov/study/NCT06522737","title":"A Multicentre, Open-label, Phase 3, Randomised Controlled Trial of Duvelisib Versus Investigator's Choice of Gemcitabine or Bendamustine in Patients With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","has_exemption":false,"start_date":"2025-05-19","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"SecuraBio","sponsor_slug":"securabio","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05730283","publication_url":"https://clinicaltrials.gov/study/NCT05730283","title":"Phase 2 Study of the Efficacy and Safety of ORC-13661 for the Prevention of Drug-Induced Hearing Loss in Patients Receiving Intravenous Amikacin Therapy for Pulmonary Non-Tuberculous Mycobacterium Disease","has_exemption":false,"start_date":"2025-06-02","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Kevin Winthrop","sponsor_slug":"kevin-winthrop","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06995677","publication_url":"https://clinicaltrials.gov/study/NCT06995677","title":"A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)","has_exemption":false,"start_date":"2025-06-27","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Tyra Biosciences, Inc","sponsor_slug":"tyra-biosciences-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06801639","publication_url":"https://clinicaltrials.gov/study/NCT06801639","title":"Advancing Alzheimer's Care: Home-based tDCS (Transcranial Direct Current Stimulator) for Affective Symptoms","has_exemption":false,"start_date":"2025-07-15","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"The University of Texas Health Science Center at San Antonio","sponsor_slug":"the-university-of-texas-health-science-center-at-san-antonio","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07055594","publication_url":"https://clinicaltrials.gov/study/NCT07055594","title":"A Phase I/IIa Dose-escalation, Dose-optimization and Dose Expansion Study to Evaluate the Safety and Preliminary Efficacy of Tri-specific Antibody (SOA101) in Subjects With Advanced Solid Tumors.","has_exemption":false,"start_date":"2025-07-30","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Shine-On Biomedical Co., Ltd.","sponsor_slug":"shine-on-biomedical-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07145918","publication_url":"https://clinicaltrials.gov/study/NCT07145918","title":"An Adaptive Two-part Randomized, Double Blind, Placebo-controlled Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Emraclidine in Participants With Schizophrenia","has_exemption":false,"start_date":"2025-08-04","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07029581","publication_url":"https://clinicaltrials.gov/study/NCT07029581","title":"A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)","has_exemption":false,"start_date":"2025-08-06","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"ACADIA Pharmaceuticals Inc.","sponsor_slug":"acadia-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07070232","publication_url":"https://clinicaltrials.gov/study/NCT07070232","title":"A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors","has_exemption":false,"start_date":"2025-08-12","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Biontech SE","sponsor_slug":"biontech-se","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06925321","publication_url":"https://clinicaltrials.gov/study/NCT06925321","title":"An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections Caused by Aspergillus Spp., Fusarium Spp., Lomentospora Prolificans, Mucorales Fungi, or Other Multidrug Resistant Molds","has_exemption":false,"start_date":"2025-08-26","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Basilea Pharmaceutica","sponsor_slug":"basilea-pharmaceutica","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06521476","publication_url":"https://clinicaltrials.gov/study/NCT06521476","title":"Impact of Acetazolamide on Central Sleep Apnea Patients Receiving Medication for Opioid Use Disorder","has_exemption":false,"start_date":"2025-09-30","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Sanjay R Patel","sponsor_slug":"sanjay-r-patel","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06800963","publication_url":"https://clinicaltrials.gov/study/NCT06800963","title":"ResQ133A-NMIBC: Phase 1/2 Clinical Trial of Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG","has_exemption":false,"start_date":"2025-10-15","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"ImmunityBio, Inc.","sponsor_slug":"immunitybio-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07221851","publication_url":"https://clinicaltrials.gov/study/NCT07221851","title":"A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents With Growth Failure or Short Stature Due to Growth Hormone Sufficient Disorders - Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature","has_exemption":false,"start_date":"2025-12-12","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Ascendis Pharma A/S","sponsor_slug":"ascendis-pharma-as","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07288320","publication_url":"https://clinicaltrials.gov/study/NCT07288320","title":"A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder Who Are Currently Experiencing a Manic Episode or Manic Episode With Mixed Features, With or Without Psychotic Symptoms, and Warrant Inpatient Hospitalization","has_exemption":false,"start_date":"2025-12-24","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Neurocrine Biosciences","sponsor_slug":"neurocrine-biosciences","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07201519","publication_url":"https://clinicaltrials.gov/study/NCT07201519","title":"Phase IIa Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy","has_exemption":false,"start_date":"2026-01-23","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Michael J Cavnar, MD","sponsor_slug":"michael-j-cavnar-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07494305","publication_url":"https://clinicaltrials.gov/study/NCT07494305","title":"A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With Major Depressive Episodes Associated With Bipolar I Disorder","has_exemption":false,"start_date":"2026-01-23","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"LB Pharmaceuticals Inc.","sponsor_slug":"lb-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07412756","publication_url":"https://clinicaltrials.gov/study/NCT07412756","title":"A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Major Depressive Disorder (RENEW-MDD 1)","has_exemption":false,"start_date":"2026-02-09","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Eli Lilly and Company","sponsor_slug":"eli-lilly-and-company","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07285005","publication_url":"https://clinicaltrials.gov/study/NCT07285005","title":"A Phase 3, Randomized, Parallel, Multicenter, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of KP 001 in Patients Aged ≥2 Years With Common Venous Malformations, Common Lymphatic Malformations, or KTS/CLOVES Syndrome","has_exemption":false,"start_date":"2026-02-26","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Kaken Pharmaceutical","sponsor_slug":"kaken-pharmaceutical","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07192731","publication_url":"https://clinicaltrials.gov/study/NCT07192731","title":"Treatment of LIVER-limited HepatoCellular Carcinoma (HCC) in Patients With Preserved Liver Function by IRreversible Electroporation: A Prospective, International, Multi-centre Cohort Study","has_exemption":false,"start_date":"2026-02-28","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Angiodynamics, Inc.","sponsor_slug":"angiodynamics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07191548","publication_url":"https://clinicaltrials.gov/study/NCT07191548","title":"Treatment of LIVER METastases From Colorectal Cancer by IRreversible Electroporation: A Prospective, International, Multi-centre Cohort Study.","has_exemption":false,"start_date":"2026-02-28","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Angiodynamics, Inc.","sponsor_slug":"angiodynamics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07296874","publication_url":"https://clinicaltrials.gov/study/NCT07296874","title":"Acute Effects of Cannabis on Cognition and Affect","has_exemption":false,"start_date":"2026-02-28","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Washington State University","sponsor_slug":"washington-state-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07404111","publication_url":"https://clinicaltrials.gov/study/NCT07404111","title":"An Adaptive Phase 1/2 MulticenteR Study Evaluating the Safety, Tolerability, Pharmacokinetics and EfficaCy of VV-14305 Delivered Via PeribuLbAr Injection in Patients With Moderate to Severe Thyroid Eye Disease (the RECLAIM Study)","has_exemption":false,"start_date":"2026-02-28","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Kriya Therapeutics, Inc.","sponsor_slug":"kriya-therapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07434635","publication_url":"https://clinicaltrials.gov/study/NCT07434635","title":"APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes","has_exemption":false,"start_date":"2026-02-28","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07355231","publication_url":"https://clinicaltrials.gov/study/NCT07355231","title":"Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Xemed LLC","sponsor_slug":"xemed-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07492160","publication_url":"https://clinicaltrials.gov/study/NCT07492160","title":"Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms After 12-18 Week Abortion or Pregnancy Loss: A Pilot and Randomized Controlled Trial","has_exemption":false,"start_date":"2026-03-16","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Maimonides Medical Center","sponsor_slug":"maimonides-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07318584","publication_url":"https://clinicaltrials.gov/study/NCT07318584","title":"Cefotetan Therapy for Escherichia Coli Bacteremia and Genitourinary Infections: a Prospective Phase II Pilot Study","has_exemption":false,"start_date":"2026-03-31","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Oregon Health and Science University","sponsor_slug":"oregon-health-and-science-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07416604","publication_url":"https://clinicaltrials.gov/study/NCT07416604","title":"A Multicenter, Randomized, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of NXT007 Prophylaxis Versus Emicizumab Prophylaxis in People With Hemophilia A","has_exemption":false,"start_date":"2026-04-30","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07429110","publication_url":"https://clinicaltrials.gov/study/NCT07429110","title":"ColoSeal™ ICD System Anastomotic Protection Pivotal Study","has_exemption":false,"start_date":"2026-04-30","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Averto Medical, Inc.","sponsor_slug":"averto-medical-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07428616","publication_url":"https://clinicaltrials.gov/study/NCT07428616","title":"A Phase 2, Single-Arm, Multicenter, Open-Label Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma","has_exemption":false,"start_date":"2026-05-31","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Exelixis","sponsor_slug":"exelixis","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07286331","publication_url":"https://clinicaltrials.gov/study/NCT07286331","title":"A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Recurrent Endometrial Cancer","has_exemption":false,"start_date":"2026-06-09","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07488988","publication_url":"https://clinicaltrials.gov/study/NCT07488988","title":"SCARFREE-001: A Phase 2 Dose-Finding and Proof-of-Concept Study of Intradermal Verteporfin for Scar Prevention in Open and Closed Surgical Wounds","has_exemption":false,"start_date":"2026-06-30","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Odense University Hospital","sponsor_slug":"odense-university-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07534709","publication_url":"https://clinicaltrials.gov/study/NCT07534709","title":"Suzetrigine Versus Placebo for Opioid-Free Recovery After Cesarean Delivery: A Randomized Controlled Trial","has_exemption":false,"start_date":"2026-06-30","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"University of Texas at Austin","sponsor_slug":"university-of-texas-at-austin","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06907485","publication_url":"https://clinicaltrials.gov/study/NCT06907485","title":"A Multicenter Study to Assess the Feasibility of Gleolan (ALA / Aminolevulinic Acid HCl) in Pediatric Brain Tumor Patients After Delayed Administration","has_exemption":false,"start_date":"2026-08-31","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Costas Hadjipanayis","sponsor_slug":"costas-hadjipanayis","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07428681","publication_url":"https://clinicaltrials.gov/study/NCT07428681","title":"Preventive Administration of Lorazepam in Critically Ill Patients With High Anttila-Index to Reduce the Incidence of Intensive Care Delirium: a Single-centre, Randomized, Controlled Clinical Trial - the Basel LOC2DEL-Trial","has_exemption":false,"start_date":"2027-03-31","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"University Hospital, Basel, Switzerland","sponsor_slug":"university-hospital-basel-switzerland","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07114679","publication_url":"https://clinicaltrials.gov/study/NCT07114679","title":"Molecular Breast Imaging (MBI)-Guided Biopsy Pilot SBIR","has_exemption":false,"start_date":"2027-06-30","completion_date":"2028-02-29","has_results":false,"results_due":false,"sponsor_name":"Smart Breast Corp.","sponsor_slug":"smart-breast-corp","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04404088","publication_url":"https://clinicaltrials.gov/study/NCT04404088","title":"A Phase II Study of Acalabrutinib, Lenalidomide, and Rituximab (aR2) in Patients With Previously Untreated Follicular Lymphoma","has_exemption":false,"start_date":"2020-07-16","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04560322","publication_url":"https://clinicaltrials.gov/study/NCT04560322","title":"A Phase 2 Study of MRD Adapted Therapy With Venetoclax-obinutuzumab in Patients With High or Intermediate BALL Risk Relapsed or Refractory CLL, With Addition of Acalabrutinib in Patients Who Fail to Achieve MRD Eradication","has_exemption":false,"start_date":"2020-10-19","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04394858","publication_url":"https://clinicaltrials.gov/study/NCT04394858","title":"A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma","has_exemption":false,"start_date":"2021-03-17","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04871139","publication_url":"https://clinicaltrials.gov/study/NCT04871139","title":"Contrast-Enhanced Mammography (CEM) for the Evaluation and Targeted Biopsy of Suspicious Mammographic Architectural Distortions","has_exemption":false,"start_date":"2021-04-08","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04826341","publication_url":"https://clinicaltrials.gov/study/NCT04826341","title":"A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors","has_exemption":false,"start_date":"2021-09-20","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04941274","publication_url":"https://clinicaltrials.gov/study/NCT04941274","title":"A Phase I/II Study of Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma","has_exemption":false,"start_date":"2021-09-29","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05488431","publication_url":"https://clinicaltrials.gov/study/NCT05488431","title":"Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)","has_exemption":false,"start_date":"2023-03-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Priscilla Hsue, MD","sponsor_slug":"priscilla-hsue-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05727904","publication_url":"https://clinicaltrials.gov/study/NCT05727904","title":"A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma","has_exemption":false,"start_date":"2023-03-30","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Iovance Biotherapeutics, Inc.","sponsor_slug":"iovance-biotherapeutics-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05623306","publication_url":"https://clinicaltrials.gov/study/NCT05623306","title":"A Double-Blinded, Randomized, Crossover Trial of Stereoencephalography- Guided Multi-Lead Deep Brain Stimulation for Treatment-Refractory Obsessive- Compulsive Disorder (SEEG-Guided DBS for OCD)","has_exemption":false,"start_date":"2023-04-13","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Katherine Scangos","sponsor_slug":"katherine-scangos","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05706025","publication_url":"https://clinicaltrials.gov/study/NCT05706025","title":"Pilot Study to Evaluate Utility of EnteroTracker® as a Minimally Invasive Sampling Method to Screen for Barrett's Esophagus and Esophageal Cancer","has_exemption":false,"start_date":"2023-05-31","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"University of Colorado, Denver","sponsor_slug":"university-of-colorado-denver","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06097468","publication_url":"https://clinicaltrials.gov/study/NCT06097468","title":"A Phase I/IIa, Single-Arm, Dose-Confirmation and Dose-Expansion Study Evaluating Changes in the Oral Microbiome of Patients With Oral Cavity Squamous Cell Carcinoma (OSCC) After Short-Term Ingestion of Nisin, a Naturally Occurring Food Preservative","has_exemption":false,"start_date":"2024-02-02","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06633913","publication_url":"https://clinicaltrials.gov/study/NCT06633913","title":"Neural Effects of Transcranial Magnetic Stimulation Using Concurrent Functional Magnetic Resonance Imaging","has_exemption":false,"start_date":"2024-04-19","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Jing Jiang","sponsor_slug":"jing-jiang","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06275776","publication_url":"https://clinicaltrials.gov/study/NCT06275776","title":"The Effect of Suturing Techniques on Aberrant Wound Recovery After Total Hip Arthroplasty","has_exemption":false,"start_date":"2024-08-28","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Reinier Haga Orthopedisch Centrum","sponsor_slug":"reinier-haga-orthopedisch-centrum","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06157099","publication_url":"https://clinicaltrials.gov/study/NCT06157099","title":"A Decentralized Phase II Randomized Controlled Trial of Atorvastatin in Resected High-Risk Melanoma","has_exemption":false,"start_date":"2024-09-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"OHSU Knight Cancer Institute","sponsor_slug":"ohsu-knight-cancer-institute","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06398106","publication_url":"https://clinicaltrials.gov/study/NCT06398106","title":"Proactive Therapeutic Drug Monitoring Versus Routine Care With the Novel Biologics in Psoriasis : a Pragmatic, Multicentric, Randomised, Controlled Study","has_exemption":false,"start_date":"2024-12-20","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"University Hospital, Ghent","sponsor_slug":"university-hospital-ghent","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06675344","publication_url":"https://clinicaltrials.gov/study/NCT06675344","title":"A Randomized, Double-blind, Clinical Trial of the Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life (ASScERT-QoL)","has_exemption":false,"start_date":"2025-01-06","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Robyn T. Domsic, MD, MPH","sponsor_slug":"robyn-t-domsic-md-mph","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06563596","publication_url":"https://clinicaltrials.gov/study/NCT06563596","title":"A Phase 2 Study of Epcoritamab, Zanubrutinib, and Rituximab (EZR) for Treatment of Relapsed or Refractory Follicular Lymphoma or Marginal Zone Lymphoma","has_exemption":false,"start_date":"2025-01-21","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Reid Merryman, MD","sponsor_slug":"reid-merryman-md","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06592833","publication_url":"https://clinicaltrials.gov/study/NCT06592833","title":"Investigating the Role of Serotonin in the Mechanism of Action of Psilocybin in Patients With Major Depressive Disorder","has_exemption":false,"start_date":"2025-02-25","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Icahn School of Medicine at Mount Sinai","sponsor_slug":"icahn-school-of-medicine-at-mount-sinai","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07216222","publication_url":"https://clinicaltrials.gov/study/NCT07216222","title":"Intracranial Recording and Stimulation of the Human Hippocampal-Amygdala Circuit During Virtual Reality Fear Conditioning","has_exemption":false,"start_date":"2025-03-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"University of California, Los Angeles","sponsor_slug":"university-of-california-los-angeles","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06580054","publication_url":"https://clinicaltrials.gov/study/NCT06580054","title":"Pembrolizumab for Orbital and Periocular Cutaneous Squamous Cell Carcinoma (cSCC)","has_exemption":false,"start_date":"2025-03-05","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"University of Michigan Rogel Cancer Center","sponsor_slug":"university-of-michigan-rogel-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06849713","publication_url":"https://clinicaltrials.gov/study/NCT06849713","title":"A Phase 2 Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","has_exemption":false,"start_date":"2025-05-16","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06959511","publication_url":"https://clinicaltrials.gov/study/NCT06959511","title":"Neoadjuvant Treatment With Zanzalintinib for Advanced Thyroid Cancer","has_exemption":false,"start_date":"2025-07-22","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06367361","publication_url":"https://clinicaltrials.gov/study/NCT06367361","title":"Non-inferiority, Controlled, Randomized, Single-blind Study for Compare Regimens of One and Two Doses of Oxfendazole Versus a Schedule of Two Doses of Triclabendazole to Treat Chronic Fascioliasis","has_exemption":false,"start_date":"2025-08-30","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Universidad Peruana Cayetano Heredia","sponsor_slug":"universidad-peruana-cayetano-heredia","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05535361","publication_url":"https://clinicaltrials.gov/study/NCT05535361","title":"A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome","has_exemption":false,"start_date":"2025-09-15","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Eclipse Regenesis, Inc.","sponsor_slug":"eclipse-regenesis-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07123454","publication_url":"https://clinicaltrials.gov/study/NCT07123454","title":"A Modular Phase I/II Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Efficacy of AZD4512 Monotherapy or in Combination With Other Anticancer Agent(s), in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (Lumi-NHL)","has_exemption":false,"start_date":"2025-09-24","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06934239","publication_url":"https://clinicaltrials.gov/study/NCT06934239","title":"A Randomized Controlled Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients","has_exemption":false,"start_date":"2025-10-15","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Jonsson Comprehensive Cancer Center","sponsor_slug":"jonsson-comprehensive-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06971731","publication_url":"https://clinicaltrials.gov/study/NCT06971731","title":"A Phase 3, Double-Blind, Randomized, Two-Period, Multicenter, Placebo-Controlled, Efficacy and Safety Study of JNT-517 for the Treatment of Participants With Phenylketonuria","has_exemption":false,"start_date":"2025-10-20","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","sponsor_slug":"otsuka-pharmaceutical-development-commercialization-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07025330","publication_url":"https://clinicaltrials.gov/study/NCT07025330","title":"A Phase IIa, Single-Site, Open-Label Study of Efgartigimod in Patients With IgG4-Related Disease","has_exemption":false,"start_date":"2025-11-12","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Stanford University","sponsor_slug":"stanford-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06377215","publication_url":"https://clinicaltrials.gov/study/NCT06377215","title":"Understanding Aided Speech Perception in Noise: Behavioral and Electrophysiological Measures","has_exemption":false,"start_date":"2025-11-16","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"University of South Florida","sponsor_slug":"university-of-south-florida","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07251491","publication_url":"https://clinicaltrials.gov/study/NCT07251491","title":"Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury","has_exemption":false,"start_date":"2026-01-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"James J. Peters Veterans Affairs Medical Center","sponsor_slug":"james-j-peters-veterans-affairs-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07265843","publication_url":"https://clinicaltrials.gov/study/NCT07265843","title":"Fibrinogen in Liver Transplant Subjects (FITS)","has_exemption":false,"start_date":"2026-01-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Trauma Hemostatis and Oxygenation Research (THOR) Network","sponsor_slug":"trauma-hemostatis-and-oxygenation-research-thor-network","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07270276","publication_url":"https://clinicaltrials.gov/study/NCT07270276","title":"The Impact of Dry Needling on Electrophysiological and Ultrasound-based Biomarkers for Myofascial Pain","has_exemption":false,"start_date":"2026-02-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Beth Israel Deaconess Medical Center","sponsor_slug":"beth-israel-deaconess-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07318688","publication_url":"https://clinicaltrials.gov/study/NCT07318688","title":"A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain Over a 24-Week Treatment Period and a 28-Week Extension","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Hope Medicine (Nanjing) Co., Ltd","sponsor_slug":"hope-medicine-nanjing-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07369310","publication_url":"https://clinicaltrials.gov/study/NCT07369310","title":"Randomized Trial on DBS Programming Based on Biomarkers vs. Standard Monopolar Review","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","sponsor_slug":"fundacio-institut-de-recerca-de-lhospital-de-la-santa-creu-i-sant-pau","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07403058","publication_url":"https://clinicaltrials.gov/study/NCT07403058","title":"Endovascular Ablation Of The Right Greater Splanchnic Nerve In Subjects Having Heart Failure With Reduced Ejection Fraction: Randomized Controlled Feasibility Trial","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Axon Therapies, Inc.","sponsor_slug":"axon-therapies-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07410598","publication_url":"https://clinicaltrials.gov/study/NCT07410598","title":"Safety and Tolerability of Patterned Stimulation for DBS in the Home Setting","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"University of Florida","sponsor_slug":"university-of-florida","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07430917","publication_url":"https://clinicaltrials.gov/study/NCT07430917","title":"A Phase II, Randomized, Placebo-Controlled, Double-Blind, Adaptive Study to Assess the Safety and Efficacy of Intravenous J147 Combined With Endovascular Therapy in Patients With Acute Ischemic Stroke","has_exemption":false,"start_date":"2026-04-20","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Abrexa Pharmaceuticals, Inc.","sponsor_slug":"abrexa-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07394608","publication_url":"https://clinicaltrials.gov/study/NCT07394608","title":"Use of Paired Non-Invasive Vagus Nerve Stimulation in Rehabilitation of Adolescents With Cerebral Palsy: An Open Label Safety Feasibility Trial","has_exemption":false,"start_date":"2026-04-30","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Icahn School of Medicine at Mount Sinai","sponsor_slug":"icahn-school-of-medicine-at-mount-sinai","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07215858","publication_url":"https://clinicaltrials.gov/study/NCT07215858","title":"Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of the Safety and Efficacy of BPL-1357 Against H1N1 Influenza Virus Challenge","has_exemption":false,"start_date":"2026-06-23","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","sponsor_slug":"national-institute-of-allergy-and-infectious-diseases-niaid","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07377526","publication_url":"https://clinicaltrials.gov/study/NCT07377526","title":"Phase 1/2 Study Of IL15-Transduced, TGFBR2 KO, TROP2 CAR- Engineered Cord Blood-Derived NK Cells Administered Intraperitoneally And Intravenously In Combination With Oral Belzutifan For The Management Of Pancreatic Cancer","has_exemption":false,"start_date":"2026-07-01","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07405190","publication_url":"https://clinicaltrials.gov/study/NCT07405190","title":"A Phase II Study of Ivonescimab as Monotherapy or in Combination With Platinum/Pemetrexed Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring Actionable Genomic Alterations (AGAs)","has_exemption":false,"start_date":"2026-08-04","completion_date":"2028-03-01","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03571945","publication_url":"https://clinicaltrials.gov/study/NCT03571945","title":"Impact of Bi-spectral Index Guided Inhalation Anaesthesia on the Incidence of Intraoperative Awareness in Indian Patient Population: A Prospective, Randomised, Multi-Centric Study","has_exemption":false,"start_date":"2018-10-10","completion_date":"2028-03-02","has_results":false,"results_due":false,"sponsor_name":"Sir Ganga Ram Hospital","sponsor_slug":"sir-ganga-ram-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05682378","publication_url":"https://clinicaltrials.gov/study/NCT05682378","title":"An Open-label, Single Arm, Multicenter Extension Study to Evaluate Long-term Safety and Tolerability of Inclisiran in Participants With Heterozygous or Homozygous Familial Hypercholesterolemia Who Have Completed the Adolescent ORION-16 or ORION-13 Studies (VICTORION-PEDS-OLE)","has_exemption":false,"start_date":"2023-02-10","completion_date":"2028-03-02","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05732402","publication_url":"https://clinicaltrials.gov/study/NCT05732402","title":"An Open-Label, Multiple-Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Different Dose Levels of Povetacicept in Subjects With Autoantibody-Associated Glomerular Diseases (RUBY-3)","has_exemption":false,"start_date":"2023-03-15","completion_date":"2028-03-02","has_results":false,"results_due":false,"sponsor_name":"Alpine Immune Sciences, Inc.","sponsor_slug":"alpine-immune-sciences-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06676579","publication_url":"https://clinicaltrials.gov/study/NCT06676579","title":"A Multi-Center, Phase II, Open Label, Randomized Trial Evaluating the Efficacy and Safety of Complement 5a Receptor Antagonist Avacopan in Crescentic IgA Nephropathy","has_exemption":false,"start_date":"2025-06-09","completion_date":"2028-03-02","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05402332","publication_url":"https://clinicaltrials.gov/study/NCT05402332","title":"A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Crossover, Trial Assessing the Efficacy, Safety, and Tolerability of AVTX-801 in Subjects With Phosphoglucomutase 1 Deficiency Related Congenital Disorders of Glycosylation (PGM1-CDG)","has_exemption":false,"start_date":"2026-10-01","completion_date":"2028-03-02","has_results":false,"results_due":false,"sponsor_name":"Eva Morava-Kozicz","sponsor_slug":"eva-morava-kozicz","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05834296","publication_url":"https://clinicaltrials.gov/study/NCT05834296","title":"Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 1/2a Study to Assess Safety, Tolerability & Efficacy of Autologous Beta-Amyloid Mutant Peptide-pulsed Dendritic Cells in Subjects With Mild-to-Moderate Alzheimer's Dementia","has_exemption":false,"start_date":"2023-07-05","completion_date":"2028-03-03","has_results":false,"results_due":false,"sponsor_name":"Alzamend Neuro, Inc.","sponsor_slug":"alzamend-neuro-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07447063","publication_url":"https://clinicaltrials.gov/study/NCT07447063","title":"The Impact of Dietary Salt on the Severity of Eczema","has_exemption":false,"start_date":"2026-03-06","completion_date":"2028-03-05","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07332091","publication_url":"https://clinicaltrials.gov/study/NCT07332091","title":"A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects With HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)","has_exemption":false,"start_date":"2026-01-22","completion_date":"2028-03-06","has_results":false,"results_due":false,"sponsor_name":"CSL Behring","sponsor_slug":"csl-behring","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03471650","publication_url":"https://clinicaltrials.gov/study/NCT03471650","title":"A Phase II Study to Evaluate the Performance of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer in Men With an Elevated PSA","has_exemption":false,"start_date":"2018-03-29","completion_date":"2028-03-07","has_results":false,"results_due":false,"sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","sponsor_slug":"sidney-kimmel-comprehensive-cancer-center-at-johns-hopkins","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06283966","publication_url":"https://clinicaltrials.gov/study/NCT06283966","title":"A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)","has_exemption":false,"start_date":"2024-02-21","completion_date":"2028-03-07","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07284420","publication_url":"https://clinicaltrials.gov/study/NCT07284420","title":"An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod","has_exemption":false,"start_date":"2025-12-19","completion_date":"2028-03-07","has_results":false,"results_due":false,"sponsor_name":"argenx","sponsor_slug":"argenx","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07318597","publication_url":"https://clinicaltrials.gov/study/NCT07318597","title":"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN13335, an Anti-PDGF-B Monoclonal Antibody, in Adults With Pulmonary Arterial Hypertension","has_exemption":false,"start_date":"2026-04-30","completion_date":"2028-03-08","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06928662","publication_url":"https://clinicaltrials.gov/study/NCT06928662","title":"Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study","has_exemption":false,"start_date":"2025-09-23","completion_date":"2028-03-09","has_results":false,"results_due":false,"sponsor_name":"Fred Hutchinson Cancer Center","sponsor_slug":"fred-hutchinson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04276870","publication_url":"https://clinicaltrials.gov/study/NCT04276870","title":"CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL)","has_exemption":false,"start_date":"2020-03-12","completion_date":"2028-03-10","has_results":false,"results_due":false,"sponsor_name":"Stephan Grupp MD PhD","sponsor_slug":"stephan-grupp-md-phd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07144280","publication_url":"https://clinicaltrials.gov/study/NCT07144280","title":"PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)","has_exemption":false,"start_date":"2025-09-29","completion_date":"2028-03-10","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07335588","publication_url":"https://clinicaltrials.gov/study/NCT07335588","title":"A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice Daily Delgocitinib Cream in Adult Participants With Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period","has_exemption":false,"start_date":"2026-05-06","completion_date":"2028-03-10","has_results":false,"results_due":false,"sponsor_name":"LEO Pharma","sponsor_slug":"leo-pharma","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06403644","publication_url":"https://clinicaltrials.gov/study/NCT06403644","title":"Evaluating the Technology and Assessing the Biological Effects of Commercially Available PhotoBioModulation Devices","has_exemption":false,"start_date":"2024-03-11","completion_date":"2028-03-11","has_results":false,"results_due":false,"sponsor_name":"United States Air Force Research Laboratory","sponsor_slug":"united-states-air-force-research-laboratory","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06926868","publication_url":"https://clinicaltrials.gov/study/NCT06926868","title":"IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC Who Are Ineligible for Anti-PD1/PD-L1 Treatment","has_exemption":false,"start_date":"2025-09-11","completion_date":"2028-03-13","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06453044","publication_url":"https://clinicaltrials.gov/study/NCT06453044","title":"A Phase 2 Study of Mosunetuzumab With Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma","has_exemption":false,"start_date":"2024-09-09","completion_date":"2028-03-14","has_results":false,"results_due":false,"sponsor_name":"City of Hope Medical Center","sponsor_slug":"city-of-hope-medical-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT01295645","publication_url":"https://clinicaltrials.gov/study/NCT01295645","title":"A Phase II Randomized Study of Cidofovir Versus Best Supportive Care for Polyomavirus Hominis Type I (BK) Virus Related Hemorrhagic Cystitis After Stem Cell Transplant","has_exemption":false,"start_date":"2011-03-17","completion_date":"2028-03-15","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT06245109","publication_url":"https://clinicaltrials.gov/study/NCT06245109","title":"Brain-Based and Clinical Phenotyping of Pain Pharmacotherapy in Knee Osteoarthritis","has_exemption":false,"start_date":"2024-02-26","completion_date":"2028-03-15","has_results":false,"results_due":false,"sponsor_name":"Northwestern University","sponsor_slug":"northwestern-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06616766","publication_url":"https://clinicaltrials.gov/study/NCT06616766","title":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion","has_exemption":false,"start_date":"2024-10-02","completion_date":"2028-03-15","has_results":false,"results_due":false,"sponsor_name":"Yuhan Corporation","sponsor_slug":"yuhan-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06605105","publication_url":"https://clinicaltrials.gov/study/NCT06605105","title":"A Phase III Long-Term Extension Trial With Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants With Major Depressive Disorder (EXTEND)","has_exemption":false,"start_date":"2025-07-18","completion_date":"2028-03-15","has_results":false,"results_due":false,"sponsor_name":"Cybin IRL Limited","sponsor_slug":"cybin-irl-limited","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06747611","publication_url":"https://clinicaltrials.gov/study/NCT06747611","title":"Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata","has_exemption":false,"start_date":"2025-08-21","completion_date":"2028-03-15","has_results":false,"results_due":false,"sponsor_name":"University of Minnesota","sponsor_slug":"university-of-minnesota","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07487831","publication_url":"https://clinicaltrials.gov/study/NCT07487831","title":"The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease","has_exemption":false,"start_date":"2026-03-16","completion_date":"2028-03-17","has_results":false,"results_due":false,"sponsor_name":"University of California, San Francisco","sponsor_slug":"university-of-california-san-francisco","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07476287","publication_url":"https://clinicaltrials.gov/study/NCT07476287","title":"A PHASE 2 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED TRANSFORMED SMALL CELL LUNG CANCER","has_exemption":false,"start_date":"2026-05-15","completion_date":"2028-03-19","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06305247","publication_url":"https://clinicaltrials.gov/study/NCT06305247","title":"An Open-label, Phase I/IIa First-in-human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Antitumour Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants With Advanced Solid Tumours","has_exemption":false,"start_date":"2024-04-03","completion_date":"2028-03-20","has_results":false,"results_due":false,"sponsor_name":"Ipsen","sponsor_slug":"ipsen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07284979","publication_url":"https://clinicaltrials.gov/study/NCT07284979","title":"A Phase 3, Randomized, Active- and Placebo-Controlled, Partially-Blinded Study to Compare the Efficacy and Safety of KAI-9531 Administered Once Weekly Versus Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes","has_exemption":false,"start_date":"2025-12-30","completion_date":"2028-03-20","has_results":false,"results_due":false,"sponsor_name":"Kailera","sponsor_slug":"kailera","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06947941","publication_url":"https://clinicaltrials.gov/study/NCT06947941","title":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Psychosis Associated With Alzheimer's Disease","has_exemption":false,"start_date":"2026-03-25","completion_date":"2028-03-20","has_results":false,"results_due":false,"sponsor_name":"Bristol-Myers Squibb","sponsor_slug":"bristol-myers-squibb","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05025800","publication_url":"https://clinicaltrials.gov/study/NCT05025800","title":"A Phase I/II Open Label, Single Center, Study of the Combination of ALX148, Rituximab and Lenalidomide in Patients With Indolent and Aggressive B-Cell Non-Hodgkin Lymphoma","has_exemption":false,"start_date":"2021-10-13","completion_date":"2028-03-21","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05160922","publication_url":"https://clinicaltrials.gov/study/NCT05160922","title":"CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES","has_exemption":false,"start_date":"2021-12-27","completion_date":"2028-03-21","has_results":false,"results_due":false,"sponsor_name":"Pfizer","sponsor_slug":"pfizer","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04804553","publication_url":"https://clinicaltrials.gov/study/NCT04804553","title":"A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD)","has_exemption":false,"start_date":"2022-03-17","completion_date":"2028-03-21","has_results":false,"results_due":false,"sponsor_name":"Amgen","sponsor_slug":"amgen","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06350097","publication_url":"https://clinicaltrials.gov/study/NCT06350097","title":"A Phase III, Open-label, Randomised Study of Osimertinib With or Without Datopotamab Deruxtecan (Dato-DXd), as First-line Treatment in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation-positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer","has_exemption":false,"start_date":"2024-04-29","completion_date":"2028-03-21","has_results":false,"results_due":false,"sponsor_name":"AstraZeneca","sponsor_slug":"astrazeneca","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06597019","publication_url":"https://clinicaltrials.gov/study/NCT06597019","title":"Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- Cholesterol","has_exemption":false,"start_date":"2024-12-09","completion_date":"2028-03-21","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06597006","publication_url":"https://clinicaltrials.gov/study/NCT06597006","title":"Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Inclisiran in Children (2 to Less Than 12 Years) With Homozygous Familial Hypercholesterolemia and Elevated LDL-cholesterol","has_exemption":false,"start_date":"2025-02-28","completion_date":"2028-03-23","has_results":false,"results_due":false,"sponsor_name":"Novartis Pharmaceuticals","sponsor_slug":"novartis-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07221188","publication_url":"https://clinicaltrials.gov/study/NCT07221188","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)","has_exemption":false,"start_date":"2025-12-12","completion_date":"2028-03-24","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07332455","publication_url":"https://clinicaltrials.gov/study/NCT07332455","title":"A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)","has_exemption":false,"start_date":"2026-02-10","completion_date":"2028-03-24","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07213973","publication_url":"https://clinicaltrials.gov/study/NCT07213973","title":"A Phase 2, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Povorcitinib in Adolescents With Moderate to Severe Hidradenitis Suppurativa","has_exemption":false,"start_date":"2026-02-02","completion_date":"2028-03-25","has_results":false,"results_due":false,"sponsor_name":"Incyte Corporation","sponsor_slug":"incyte-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05530421","publication_url":"https://clinicaltrials.gov/study/NCT05530421","title":"Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge Study)","has_exemption":false,"start_date":"2023-03-26","completion_date":"2028-03-26","has_results":false,"results_due":false,"sponsor_name":"University of Miami","sponsor_slug":"university-of-miami","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07284901","publication_url":"https://clinicaltrials.gov/study/NCT07284901","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes","has_exemption":false,"start_date":"2026-01-12","completion_date":"2028-03-27","has_results":false,"results_due":false,"sponsor_name":"Kailera","sponsor_slug":"kailera","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05616910","publication_url":"https://clinicaltrials.gov/study/NCT05616910","title":"Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury","has_exemption":false,"start_date":"2025-04-06","completion_date":"2028-03-28","has_results":false,"results_due":false,"sponsor_name":"University of Pennsylvania","sponsor_slug":"university-of-pennsylvania","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06939348","publication_url":"https://clinicaltrials.gov/study/NCT06939348","title":"Safety and Efficacy of Thalamic Focused Ultrasound Stimulation (tFUS) for Promoting Recovery After Severe Traumatic Brain Injury","has_exemption":false,"start_date":"2025-04-26","completion_date":"2028-03-28","has_results":false,"results_due":false,"sponsor_name":"University of California, Los Angeles","sponsor_slug":"university-of-california-los-angeles","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07136181","publication_url":"https://clinicaltrials.gov/study/NCT07136181","title":"A Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma","has_exemption":false,"start_date":"2025-11-20","completion_date":"2028-03-28","has_results":false,"results_due":false,"sponsor_name":"Novelwise Pharmaceutical Corporation","sponsor_slug":"novelwise-pharmaceutical-corporation","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07290140","publication_url":"https://clinicaltrials.gov/study/NCT07290140","title":"A Randomized, Controlled, Blinded, Multi-Center Trial to Assess the Safety and Efficacy of Paclitaxel-Coated Sinus Balloon as an Adjunct to Endoscopic Sinus Surgery in Adult Chronic Rhinosinusitis Subjects","has_exemption":false,"start_date":"2026-03-01","completion_date":"2028-03-28","has_results":false,"results_due":false,"sponsor_name":"Airiver Medical, Inc.","sponsor_slug":"airiver-medical-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07508787","publication_url":"https://clinicaltrials.gov/study/NCT07508787","title":"Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids","has_exemption":false,"start_date":"2026-04-29","completion_date":"2028-03-28","has_results":false,"results_due":false,"sponsor_name":"Nefro Avillion Clinical Development, LLC","sponsor_slug":"nefro-avillion-clinical-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07221227","publication_url":"https://clinicaltrials.gov/study/NCT07221227","title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)","has_exemption":false,"start_date":"2025-10-24","completion_date":"2028-03-29","has_results":false,"results_due":false,"sponsor_name":"GlaxoSmithKline","sponsor_slug":"glaxosmithkline","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07298473","publication_url":"https://clinicaltrials.gov/study/NCT07298473","title":"Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)","has_exemption":false,"start_date":"2026-04-08","completion_date":"2028-03-29","has_results":false,"results_due":false,"sponsor_name":"Medtronic Cardiac Ablation Solutions","sponsor_slug":"medtronic-cardiac-ablation-solutions","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03950609","publication_url":"https://clinicaltrials.gov/study/NCT03950609","title":"A Phase II Study of Lenvatinib in Combination With Everolimus in Patients With Advanced Carcinoid Tumors","has_exemption":false,"start_date":"2019-07-30","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05027633","publication_url":"https://clinicaltrials.gov/study/NCT05027633","title":"Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)","has_exemption":false,"start_date":"2021-11-02","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05316155","publication_url":"https://clinicaltrials.gov/study/NCT05316155","title":"Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Participants With Non-Muscle-Invasive or Muscle-Invasive Bladder Cancer","has_exemption":false,"start_date":"2022-04-11","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Janssen Research & Development, LLC","sponsor_slug":"janssen-research-development-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05811364","publication_url":"https://clinicaltrials.gov/study/NCT05811364","title":"The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease","has_exemption":false,"start_date":"2023-10-17","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"W.L.Gore & Associates","sponsor_slug":"wlgore-associates","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06091865","publication_url":"https://clinicaltrials.gov/study/NCT06091865","title":"A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)","has_exemption":false,"start_date":"2023-12-13","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Regeneron Pharmaceuticals","sponsor_slug":"regeneron-pharmaceuticals","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06213324","publication_url":"https://clinicaltrials.gov/study/NCT06213324","title":"Neural Circuit-Specific Mechanisms of Ketamine's Effect on Anhedonia and Anxiety in Depression Using Ultra-High Field 7-Tesla MRI","has_exemption":false,"start_date":"2024-01-31","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Icahn School of Medicine at Mount Sinai","sponsor_slug":"icahn-school-of-medicine-at-mount-sinai","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06644768","publication_url":"https://clinicaltrials.gov/study/NCT06644768","title":"A Multicenter, Randomized, Open-Label, Phase 1b/2 Trial Of Valemetostat Tosylate Plus Pembrolizumab Vs Pembrolizumab Alone in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 With Tumor Proportion Score ≥50% Without Actionable Genomic Alterations","has_exemption":false,"start_date":"2024-10-30","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Daiichi Sankyo","sponsor_slug":"daiichi-sankyo","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06565507","publication_url":"https://clinicaltrials.gov/study/NCT06565507","title":"A Double-blind Multicenter, Randomized Controlled Trial of Single and Multiple Dose Regimens of Oxfendazole for Mild (One or Two Lesions) Parenchymal Brain Cysticercosis, With an Open Comparison Group","has_exemption":false,"start_date":"2024-12-15","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Universidad Peruana Cayetano Heredia","sponsor_slug":"universidad-peruana-cayetano-heredia","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06877650","publication_url":"https://clinicaltrials.gov/study/NCT06877650","title":"A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JMT108 Injection in Participants With Advanced Malignant Tumors.","has_exemption":false,"start_date":"2025-04-11","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Shanghai JMT-Bio Inc.","sponsor_slug":"shanghai-jmt-bio-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT06905054","publication_url":"https://clinicaltrials.gov/study/NCT06905054","title":"Peroxisome Proliferator-Activated Receptor Agonists to Prevent Primary Sclerosing Cholangitis Recurrence After Liver Transplantation","has_exemption":false,"start_date":"2025-04-15","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07166757","publication_url":"https://clinicaltrials.gov/study/NCT07166757","title":"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Human Allogeneic Induced Pluripotent Stem Cell-derived Dopaminergic Neural Progenitor Cell Injection in the Treatment of Early-onset Parkinson's Disease","has_exemption":false,"start_date":"2025-09-22","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.","sponsor_slug":"xellsmart-bio-pharmaceutical-suzhou-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07169175","publication_url":"https://clinicaltrials.gov/study/NCT07169175","title":"A Multicenter, Open-label, Single-arm, Dose Escalation and Expansion, Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SNUG01 in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)","has_exemption":false,"start_date":"2025-12-01","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"SineuGene Therapeutics Co., Ltd.","sponsor_slug":"sineugene-therapeutics-co-ltd","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07115329","publication_url":"https://clinicaltrials.gov/study/NCT07115329","title":"Phase 2, Multicenter, Randomized, Double-Blind Evaluation of the Efficacy and Safety of Oral GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder","has_exemption":false,"start_date":"2026-01-05","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Syndeio Biosciences, Inc","sponsor_slug":"syndeio-biosciences-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07350174","publication_url":"https://clinicaltrials.gov/study/NCT07350174","title":"A Multicenter, Open-label, Randomized, Active-controlled, Phase 2a Study to Evaluate the Pharmacokinetics and Safety of Alpibectir/Ethionamide in Combination With the Standard Regimen in Patients With Tuberculosis Meningitis.","has_exemption":false,"start_date":"2026-03-30","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"BioVersys AG","sponsor_slug":"bioversys-ag","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT07403968","publication_url":"https://clinicaltrials.gov/study/NCT07403968","title":"An Open-Label, Single-Arm, Phase 2a Trial to Evaluate the Safety, Tolerability, PK, and Mechanism of Action of Zasocitinib (TAK-279) in Participants With Active Crohn's Disease","has_exemption":false,"start_date":"2026-05-16","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Takeda","sponsor_slug":"takeda","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03514329","publication_url":"https://clinicaltrials.gov/study/NCT03514329","title":"Vapor Ablation for Localized Cancer Lesions of the Lung - A Clinical Feasibility Definitive Treatment Study","has_exemption":false,"start_date":"2026-09-01","completion_date":"2028-03-30","has_results":false,"results_due":false,"sponsor_name":"Uptake Medical Technology, Inc.","sponsor_slug":"uptake-medical-technology-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03414502","publication_url":"https://clinicaltrials.gov/study/NCT03414502","title":"Treatment of Rheumatoid Arthritis With Disease-modifying Antirheumatic Drugs (DMARDs): Predictors of Response","has_exemption":false,"start_date":"2007-12-10","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Nebraska","sponsor_slug":"university-of-nebraska","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02174549","publication_url":"https://clinicaltrials.gov/study/NCT02174549","title":"Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer","has_exemption":false,"start_date":"2014-09-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Teclison Ltd.","sponsor_slug":"teclison-ltd","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02324387","publication_url":"https://clinicaltrials.gov/study/NCT02324387","title":"Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women With Locoregional Invasive Breast Cancer Using Tc99m Sestamibi Molecular Breast Imaging: A Prospective Study","has_exemption":false,"start_date":"2015-06-15","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02710968","publication_url":"https://clinicaltrials.gov/study/NCT02710968","title":"Study of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Fetuses With Severe Left Congenital Diaphragmatic Hernia (CDH)","has_exemption":false,"start_date":"2015-08-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Johns Hopkins University","sponsor_slug":"johns-hopkins-university","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02629809","publication_url":"https://clinicaltrials.gov/study/NCT02629809","title":"First-Line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-Del(17p)","has_exemption":false,"start_date":"2016-03-18","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02742883","publication_url":"https://clinicaltrials.gov/study/NCT02742883","title":"A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG)","has_exemption":false,"start_date":"2016-04-13","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Burzynski Research Institute","sponsor_slug":"burzynski-research-institute","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02703623","publication_url":"https://clinicaltrials.gov/study/NCT02703623","title":"A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer","has_exemption":false,"start_date":"2016-05-18","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"M.D. Anderson Cancer Center","sponsor_slug":"md-anderson-cancer-center","status":"ongoing","is_pact":true,"days_late":null},{"registry_id":"NCT02724579","publication_url":"https://clinicaltrials.gov/study/NCT02724579","title":"A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients","has_exemption":false,"start_date":"2017-11-17","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Children's Oncology Group","sponsor_slug":"childrens-oncology-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03682289","publication_url":"https://clinicaltrials.gov/study/NCT03682289","title":"Phase II Trial of Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Selected Solid Tumor Malignancies","has_exemption":false,"start_date":"2019-01-17","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Rahul Aggarwal","sponsor_slug":"rahul-aggarwal","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03865290","publication_url":"https://clinicaltrials.gov/study/NCT03865290","title":"Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia","has_exemption":false,"start_date":"2019-04-02","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT03998254","publication_url":"https://clinicaltrials.gov/study/NCT03998254","title":"A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age","has_exemption":false,"start_date":"2019-06-26","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Merck Sharp & Dohme LLC","sponsor_slug":"merck-sharp-dohme-llc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04099056","publication_url":"https://clinicaltrials.gov/study/NCT04099056","title":"Brain Stimulation Studies of Decision-making Using Repetitive Transcranial Magnetic Stimulation (rTMS) and Temporal Interference (TI)","has_exemption":false,"start_date":"2019-11-11","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Emory University","sponsor_slug":"emory-university","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04261712","publication_url":"https://clinicaltrials.gov/study/NCT04261712","title":"An Open Label, Long-term Extension Study to Evaluate the Safety and Efficacy of CRN00808 in Subjects With Acromegaly (ACROBAT Advance)","has_exemption":false,"start_date":"2020-01-29","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Crinetics Pharmaceuticals Inc.","sponsor_slug":"crinetics-pharmaceuticals-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04248452","publication_url":"https://clinicaltrials.gov/study/NCT04248452","title":"A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)","has_exemption":false,"start_date":"2020-05-26","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"ECOG-ACRIN Cancer Research Group","sponsor_slug":"ecog-acrin-cancer-research-group","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04560803","publication_url":"https://clinicaltrials.gov/study/NCT04560803","title":"Using Autologous Epidermal Skin Micrografts to Improve Healing In Radiation Wounds: A Pilot Study","has_exemption":false,"start_date":"2021-01-19","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Massachusetts General Hospital","sponsor_slug":"massachusetts-general-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04230356","publication_url":"https://clinicaltrials.gov/study/NCT04230356","title":"A Randomized Trial of Scheduled Versus Treatment Administration of Donor-Derived Viral Specific T-cells (VSTs) for Control of Viral Infections After Allogeneic Stem Cell Transplant","has_exemption":false,"start_date":"2021-01-27","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Children's Hospital Medical Center, Cincinnati","sponsor_slug":"childrens-hospital-medical-center-cincinnati","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04408638","publication_url":"https://clinicaltrials.gov/study/NCT04408638","title":"A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma","has_exemption":false,"start_date":"2021-02-23","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Hoffmann-La Roche","sponsor_slug":"hoffmann-la-roche","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04696029","publication_url":"https://clinicaltrials.gov/study/NCT04696029","title":"Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma","has_exemption":false,"start_date":"2021-03-29","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Giselle Sholler","sponsor_slug":"giselle-sholler","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04786223","publication_url":"https://clinicaltrials.gov/study/NCT04786223","title":"Targeting Neuroinflammation as a Contributing Pathology in Alzheimer's Disease Dementia and Related Dementias","has_exemption":false,"start_date":"2021-03-30","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Val Lowe","sponsor_slug":"val-lowe","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04848506","publication_url":"https://clinicaltrials.gov/study/NCT04848506","title":"A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)","has_exemption":false,"start_date":"2021-05-06","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Cytokinetics","sponsor_slug":"cytokinetics","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04486833","publication_url":"https://clinicaltrials.gov/study/NCT04486833","title":"A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2021-09-03","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Genprex, Inc.","sponsor_slug":"genprex-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05150704","publication_url":"https://clinicaltrials.gov/study/NCT05150704","title":"Single Blind Randomized Controlled Trial to Assess the Safety and Efficacy of High Dose Pulse Intravenous Corticosteroid Therapy to Treat Patients With Complicated/Fulminant Acute Myocarditis","has_exemption":false,"start_date":"2021-10-07","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Niguarda Hospital","sponsor_slug":"niguarda-hospital","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04982419","publication_url":"https://clinicaltrials.gov/study/NCT04982419","title":"Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial","has_exemption":false,"start_date":"2021-11-01","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"VA Office of Research and Development","sponsor_slug":"va-office-of-research-and-development","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04853251","publication_url":"https://clinicaltrials.gov/study/NCT04853251","title":"A Phase IV, Multicenter, Open-label Study to Assess Corneal Endothelial Cells in Patients With Neovascular Age-related Macular Degeneration Treated With the Port Delivery System With Ranibizumab (PDS)","has_exemption":false,"start_date":"2021-12-14","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Genentech, Inc.","sponsor_slug":"genentech-inc","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04840602","publication_url":"https://clinicaltrials.gov/study/NCT04840602","title":"A Phase II Randomized Study Comparing BTK Inhibitors (Ibrutinib Plus Rituximab or Zanubrutinib Alone) vs. BCL-2 Inhibitor (Venetoclax) and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) / Lymphoplasmacytic Lymphoma (LPL)","has_exemption":false,"start_date":"2022-01-05","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"National Cancer Institute (NCI)","sponsor_slug":"national-cancer-institute-nci","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04977180","publication_url":"https://clinicaltrials.gov/study/NCT04977180","title":"Phase II Trial of Cardioprotective Prophylaxis With Combination of Beta Blocker and Angiotensin-Converting Enzyme Inhibitors During Intensive Chemotherapy for Patients With Newly Diagnosed Acute Myeloid Leukemia","has_exemption":false,"start_date":"2022-03-04","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Virginia","sponsor_slug":"university-of-virginia","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT04928846","publication_url":"https://clinicaltrials.gov/study/NCT04928846","title":"A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer","has_exemption":false,"start_date":"2022-03-25","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"AbbVie","sponsor_slug":"abbvie","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05269381","publication_url":"https://clinicaltrials.gov/study/NCT05269381","title":"A Phase I/II Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)","has_exemption":false,"start_date":"2022-03-31","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Mayo Clinic","sponsor_slug":"mayo-clinic","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05376267","publication_url":"https://clinicaltrials.gov/study/NCT05376267","title":"Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP)","has_exemption":false,"start_date":"2022-08-05","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"University of Michigan","sponsor_slug":"university-of-michigan","status":"ongoing","is_pact":false,"days_late":null},{"registry_id":"NCT05523947","publication_url":"https://clinicaltrials.gov/study/NCT05523947","title":"A Phase 1/2, Open-label, Multicenter, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of YH32367 in Patients With HER2-Positive Locally Advanced or Metastatic Solid Tumors","has_exemption":false,"start_date":"2022-08-26","completion_date":"2028-03-31","has_results":false,"results_due":false,"sponsor_name":"Yuhan Corporation","sponsor_slug":"yuhan-corporation","status":"ongoing","is_pact":false,"days_late":null}]}